Axsome Therapeutics (AXSM) Valuation After SUNOSI Patent Settlement Extends Generic Entry Timeline

Simply Wall St

Wed, February 18, 2026 at 2:11 PM GMT+9 3 min read

In this article:

AXSM

+1.15%

ALKEM.BO

-0.92%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Axsome Therapeutics (AXSM) shares are in focus after the company settled patent litigation with Alkem Laboratories over its SUNOSI product, setting licensed generic entry dates starting in 2040, subject to regulatory approvals.

See our latest analysis for Axsome Therapeutics.

The legal settlement arrives after a strong run in the shares, with a 90 day share price return of 24.89% and a 1 year total shareholder return of 43.10%, suggesting momentum has been building over both shorter and longer horizons.

If Axsome’s legal win has you thinking about where the next growth stories could come from in healthcare, it may be worth scanning 25 healthcare AI stocks as a starting point for other ideas.

With Axsome valued at $183.30 a share, a value score of 3 and an intrinsic discount flag of 0.74, is the recent legal clarity creating a genuine opportunity, or is the market already pricing in years of future growth?

Most Popular Narrative: 14.9% Undervalued

Axsome Therapeutics’ most followed narrative pegs fair value at $215.44 per share versus the last close of $183.30, framing the legal update against a richer long term story.

The company is advancing multiple late stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Read the complete narrative.

Curious what has to happen for that valuation to make sense? The narrative leans on rapid revenue expansion, sharply improving margins, and a richer earnings multiple. The exact assumptions may surprise you.

On this view, the gap between the current $183.30 share price and the $215.44 fair value comes from a model that applies a 6.98% discount rate to forecasted cash flows, combines strong revenue growth with a swing into profitability, and assumes the market is willing to pay a higher P/E multiple for those future earnings.

Result: Fair Value of $215.44 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this upbeat story still runs into real pressure points, including heavy reliance on Auvelity and Sunosi, as well as ongoing net losses and liquidity risks if execution falls short.

Find out about the key risks to this Axsome Therapeutics narrative.

Another Way To Look At Valuation

That 14.9% gap between fair value of $215.44 and the $183.30 share price rests on upbeat growth and margin forecasts. Yet on simple P/S, Axsome trades at 16.5x, well above the US Pharmaceuticals average of 4.3x and slightly above its own 16.1x fair ratio. Is the premium more comfort or more risk?

Story Continues  

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:AXSM P/S Ratio as at Feb 2026

Next Steps

If this all sounds optimistic, it is worth seeing the numbers for yourself and deciding how strong the upside really looks. Take a closer look at the company’s 2 key rewards to see what others view as the key positives.

Looking for more investment ideas?

If Axsome has sharpened your focus on healthcare, do not stop here. Widen your watchlist with a few targeted screens that surface different types of opportunities.

Target reliable cash generators by checking companies flagged in our 13 dividend fortresses, where income potential sits front and center.

Hunt for potential mispricings with the 56 high quality undervalued stocks, highlighting stocks that screen as quality yet trade below estimated worth.

Prioritize resilience by scanning the 80 resilient stocks with low risk scores, built to spotlight businesses with lower risk scores that may suit steadier portfolios.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include AXSM.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info